BioCryst Shares 96-Week Orladeyo Data Highlighting 80% Reduction In HAE Attacks

  • BioCryst Pharmaceuticals Inc BCRX has announced 96-week data from the Phase 3 APeX-2 trial for Orladeyo (berotralstat), showing a sustained reduction in hereditary angioedema (HAE) attacks patients.
  • The HAE patients who were randomized to receive 150 mg of oral, once-daily Orladeyo at the start of the trial had an 80% average reduction in their mean attack rate per month during weeks 25-96 of the trial, compared to baseline. 
  • Median attack rates also decreased from 2.7 attacks/month at baseline to 0.0 attacks per month in 16 of 17 months through the same period.
  • Orladeyo was generally well-tolerated during the treatment period, with fewer drug-related adverse events reported in part 3 (weeks 49-96) as compared to part 1 (weeks 0-24) and part 2 (weeks 25-48). 81% of the patients who entered part 3 completed the trial.
  • The new data also showed a reduction in on-demand medication use in HAE patients treated with Orladeyo.
  • Orladeyo demonstrated consistently low attack rates in adolescent patients (ages 12-17), with the mean attack rate at week 4 was 0.4 attacks/month, which was generally sustained through week 48.
  • Median attack rates in these adolescents were 0.0 attacks/month throughout the 48 weeks of treatment.
  • Over 70% of patients were attack-free in weeks 4 to 48.
  • Price Action: BCRX shares are up 0.85% at $16.50 premarket on the last check Monday.

Posted In: Briefshereditary angioedemaBiotechNewsHealth CareGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.